58
Participants
Start Date
February 20, 2023
Primary Completion Date
March 30, 2025
Study Completion Date
April 30, 2027
Selinexor
Selinexor 60mg, PO d3,10,17
Azacitidine
Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16
Venetoclax
Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
NOT_YET_RECRUITING
Changzhou Municipal No.1 People's Hospital, Changzhou
NOT_YET_RECRUITING
Sichuan Provincial People's Hospital, Chengdu
NOT_YET_RECRUITING
Jilin University China Japan Union Hospital, Ch’ang-ch’un
NOT_YET_RECRUITING
Harbin Institute of Hematology and Oncology, Ha’erbin
NOT_YET_RECRUITING
Anhui Provincial Hospital, Hefei
NOT_YET_RECRUITING
the first hospital of Jiaxing affiliated hospital of Jiaxing University, Jiaxing
NOT_YET_RECRUITING
Gansu Provincial People's Hospital, Lanzhou
NOT_YET_RECRUITING
Lanzhou University NO.2 Hospital, Lanzhou
NOT_YET_RECRUITING
Ningbo Medical Center Lihuili Huspital, Ningbo
NOT_YET_RECRUITING
Shanghai Ruijin Hospital, Shanghai
RECRUITING
Shanghai Tong Ren hospital, Shanghai
NOT_YET_RECRUITING
The First Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
The First Hospital of Hebei Medical University, Shijia Zhuang
NOT_YET_RECRUITING
The Second Hospital of Hebei Medical University, Shijia Zhuang
NOT_YET_RECRUITING
First Affiliated Hospital of Xinjiang Medical University, Ürümqi
NOT_YET_RECRUITING
the Second Affiliated Hospital of Wannan Medical College, Wuhu
NOT_YET_RECRUITING
Xi'an International Medical Center, Xi'an
NOT_YET_RECRUITING
Northern Jiangsu People's Hospital, Yangzhou
NOT_YET_RECRUITING
Yixing People's Hospital, Yixing
Shanghai Tong Ren Hospital
OTHER